Plain-English Summary
Semaglutide AUD Phase 2 studied semaglutide in Adults with alcohol use disorder in an early-phase human laboratory trial. Low-dose semaglutide reduced craving and some drinking outcomes.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
80/100
Useful Public Evidence
- Evidence tier
- 92/100, weight 18%
- Design strength
- 100/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 58/100, weight 16%
- Limitations transparency
- 70/100, weight 12%
- Safety signal usefulness
- 69/100, weight 10%
- Publication/source strength
- 88/100, weight 10%
Useful for context, but limited by endpoint relevance, safety signal usefulness, limitations transparency.
How the study framework works ->Key Findings
- Low-dose semaglutide reduced craving and some drinking outcomes.
- Findings support larger randomized clinical trials of GLP-1 receptor agonists for alcohol use disorder.
Limitations
- Small early-phase trial.
- Short duration.
- Not sufficient to establish semaglutide as an approved AUD treatment.
Why It Matters
Alcohol self-administration and drinking-related outcomes
Viral Vitalism Verdict
Useful evidence, bounded by design: Small early-phase trial.
Sources
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder - JAMA Psychiatry / PubMed
- Semaglutide for Alcohol Use Disorder - ClinicalTrials.gov
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
GLP-1s, Dopamine, and Addiction: The Substance Use Signal
GLP-1 medications may do more than reduce appetite for food. Early clinical trials, real-world data, and preclinical research suggest they may also affect craving, reward, alcohol intake, and substance-use patterns - but the science is still developing.
VV Signal Score
57
Early or context-dependent
- Sources
- 19
- Studies
- 8
- Claims
- 3
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
glp 1: Early randomized human studies suggest GLP-1 receptor agonists may
Early randomized human studies suggest GLP-1 receptor agonists may reduce some alcohol craving or drinking outcomes, but the evidence is not yet sufficient for routine addiction treatment.
glp 1: GLP-1 signaling may modulate reward-related circuits, but GLP-1 medicines
GLP-1 signaling may modulate reward-related circuits, but GLP-1 medicines are not dopamine blockers and mechanistic plausibility is not proof of clinical benefit.
glp 1: Semaglutide and tirzepatide should not be collapsed into one
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
semaglutide: Semaglutide reduced major adverse cardiovascular events in SELECT participants
Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.
semaglutide: Semaglutide reduced body weight in adults with obesity or
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.